Cécile Chartier
Director/Board Member chez CELLECTIS S.A.
Profil
Cécile Chartier is currently working as a Director at Cellectis SA and as the Chief Scientific Officer at NextVivo, Inc. She holds a doctorate degree from Universite Louis Pasteur Strasbourg I.
Postes actifs de Cécile Chartier
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTIS S.A. | Director/Board Member | 27/06/2023 |
NextVivo, Inc.
 NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - |
Formation de Cécile Chartier
| Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| Entreprise privées | 1 |
|---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
